Skip to main content
R

RACURA ONCOLOGY LTD — Investor Relations & Filings

Ticker · RAC ISIN · AU000000RAC3 LEI · 9845004A1AE3E97Q1296 ASX Professional, scientific and technical activities
Open in API
Filings indexed 133 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country AU Australia
Listing ASX RAC

About RACURA ONCOLOGY LTD

https://racuraoncology.com/

Racura Oncology Ltd is a clinical-stage entity focused on the development of precision oncology therapeutics. The organization specializes in the inhibition of the Fat Mass and Obesity-associated (FTO) protein, a key regulator of m6A RNA methylation involved in cancer progression. Its primary therapeutic candidate, Bisantrene, is a small molecule inhibitor designed to address FTO-driven pathways in acute myeloid leukemia and various solid tumors. The company’s research program explores the cardioprotective benefits and anti-tumor efficacy of its lead compounds, targeting specific molecular drivers of disease. By focusing on the intersection of RNA epigenetics and targeted therapy, the company seeks to overcome treatment resistance and improve patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - RAC 5 pages 16.3KB
Regulatory Filings Classification · 1% confidence The document is an ASX Appendix 3H notification detailing the cessation (lapse) of unquoted equity options (“securities that have ceased”) for Racura Oncology Ltd. It is a regulatory announcement to the exchange about capital changes but not a new share issue, dividend notice, or earnings report. It does not fit any specific category such as earnings release, dividend notice, M&A, or share issue. Therefore it falls into the fallback category of general regulatory filings (RNS).
2026-04-23 English
Application for quotation of securities - RAC 8 pages 20.8KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 2A form titled “Application for quotation of securities,” detailing the issue and quotation of additional ordinary shares following conversion of options. It is an announcement of a share issuance/capital change, fitting the “Share Issue/Capital Change” category. This is not a full financial report, dividend notice, or AGM material, but a notification of new securities to be quoted.
2026-04-22 English
Racura presents MYC silencing data at AACR 2026 3 pages 993.8KB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement of scientific data presentation at the AACR Annual Meeting (preclinical mechanism‐of‐action poster). It is not a financial report (annual, interim, earnings release), not management change, not capital/financing, and not any transaction or dividend notice. It is a general regulatory announcement filed on ASX. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-04-21 English
Application for quotation of securities - RAC 8 pages 20.8KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 2A “Application for quotation of securities” detailing the listing of newly issued ordinary shares following the exercise of options. This constitutes an announcement of a share issue/capital change. Under the taxonomy, this falls into Share Issue/Capital Change (Code: SHA).
2026-04-15 English
Application for quotation of securities - RAC 8 pages 20.8KB
Regulatory Filings
2026-04-08 English
Racura Singapore and HK Investor Briefing Update 2 pages 635.2KB
Regulatory Filings
2026-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.